Report Detail

Other Global Primary Biliary Cholangitis Therapeutics Market Size, Status and Forecast 2019-2025

  • RnM3573112
  • |
  • 04 July, 2019
  • |
  • Global
  • |
  • 92 Pages
  • |
  • QYResearch
  • |
  • Other

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.
There is a dire need for curative therapy for primary biliary cholangitis across the world. This is because of the recurring nature of the disease. Currently, the only cure for the condition is a liver transplant. This method of treatment makes it difficult for patients to lead a normal life even with post-surgery treatment. This has resulted in research on stem cell transplantation to replace destroyed cells in the bile duct.
In 2018, the global Primary Biliary Cholangitis Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Primary Biliary Cholangitis Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Biliary Cholangitis Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Abbott Laboratories
Allergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.
...

Market segment by Type, the product can be split into
OCALIVA
Ursodiol
Others

Market segment by Application, split into
Hospital
Private Clinic
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Primary Biliary Cholangitis Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Primary Biliary Cholangitis Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Primary Biliary Cholangitis Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 OCALIVA
      • 1.4.3 Ursodiol
      • 1.4.4 Others
    • 1.5 Market by Application
      • 1.5.1 Global Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2025)
      • 1.5.2 Hospital
      • 1.5.3 Private Clinic
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Primary Biliary Cholangitis Therapeutics Market Size
    • 2.2 Primary Biliary Cholangitis Therapeutics Growth Trends by Regions
      • 2.2.1 Primary Biliary Cholangitis Therapeutics Market Size by Regions (2019-2025)
      • 2.2.2 Primary Biliary Cholangitis Therapeutics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Primary Biliary Cholangitis Therapeutics Market Size by by Players
      • 3.1.1 Global Primary Biliary Cholangitis Therapeutics Revenue by by Players (2014-2019)
      • 3.1.2 Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Primary Biliary Cholangitis Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Primary Biliary Cholangitis Therapeutics Key Players Head office and Area Served
    • 3.3 Key Players Primary Biliary Cholangitis Therapeutics Product/Solution/Service
    • 3.4 Date of Enter into Primary Biliary Cholangitis Therapeutics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Primary Biliary Cholangitis Therapeutics Market Size by Type (2014-2019)
    • 4.2 Global Primary Biliary Cholangitis Therapeutics Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 5.2 Primary Biliary Cholangitis Therapeutics Key Players in North America
    • 5.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 5.4 North America Primary Biliary Cholangitis Therapeutics Market Size by Application

    6 Europe

    • 6.1 Europe Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 6.2 Primary Biliary Cholangitis Therapeutics Key Players in Europe
    • 6.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 6.4 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application

    7 China

    • 7.1 China Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 7.2 Primary Biliary Cholangitis Therapeutics Key Players in China
    • 7.3 China Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 7.4 China Primary Biliary Cholangitis Therapeutics Market Size by Application

    8 Japan

    • 8.1 Japan Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 8.2 Primary Biliary Cholangitis Therapeutics Key Players in Japan
    • 8.3 Japan Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 8.4 Japan Primary Biliary Cholangitis Therapeutics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 9.2 Primary Biliary Cholangitis Therapeutics Key Players in Southeast Asia
    • 9.3 Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 9.4 Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size by Application

    10 India

    • 10.1 India Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 10.2 Primary Biliary Cholangitis Therapeutics Key Players in India
    • 10.3 India Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 10.4 India Primary Biliary Cholangitis Therapeutics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Primary Biliary Cholangitis Therapeutics Market Size (2014-2019)
    • 11.2 Primary Biliary Cholangitis Therapeutics Key Players in Central & South America
    • 11.3 Central & South America Primary Biliary Cholangitis Therapeutics Market Size by Type
    • 11.4 Central & South America Primary Biliary Cholangitis Therapeutics Market Size by Application

    12 International Players Profiles

    • 12.1 Abbott Laboratories
      • 12.1.1 Abbott Laboratories Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Primary Biliary Cholangitis Therapeutics Introduction
      • 12.1.4 Abbott Laboratories Revenue in Primary Biliary Cholangitis Therapeutics Business (2014-2019))
      • 12.1.5 Abbott Laboratories Recent Development
    • 12.2 Allergan Plc
      • 12.2.1 Allergan Plc Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Primary Biliary Cholangitis Therapeutics Introduction
      • 12.2.4 Allergan Plc Revenue in Primary Biliary Cholangitis Therapeutics Business (2014-2019)
      • 12.2.5 Allergan Plc Recent Development
    • 12.3 Eli Lilly and Co.
      • 12.3.1 Eli Lilly and Co. Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Primary Biliary Cholangitis Therapeutics Introduction
      • 12.3.4 Eli Lilly and Co. Revenue in Primary Biliary Cholangitis Therapeutics Business (2014-2019)
      • 12.3.5 Eli Lilly and Co. Recent Development
    • 12.4 Intercept Pharmaceuticals Inc.
      • 12.4.1 Intercept Pharmaceuticals Inc. Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Primary Biliary Cholangitis Therapeutics Introduction
      • 12.4.4 Intercept Pharmaceuticals Inc. Revenue in Primary Biliary Cholangitis Therapeutics Business (2014-2019)
      • 12.4.5 Intercept Pharmaceuticals Inc. Recent Development
    • 12.5 Takeda Pharmaceutical Co. Ltd.
      • 12.5.1 Takeda Pharmaceutical Co. Ltd. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Primary Biliary Cholangitis Therapeutics Introduction
      • 12.5.4 Takeda Pharmaceutical Co. Ltd. Revenue in Primary Biliary Cholangitis Therapeutics Business (2014-2019)
      • 12.5.5 Takeda Pharmaceutical Co. Ltd. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on Primary Biliary Cholangitis Therapeutics . Industry analysis & Market Report on Primary Biliary Cholangitis Therapeutics is a syndicated market report, published as Global Primary Biliary Cholangitis Therapeutics Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Primary Biliary Cholangitis Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,014.70
      4,522.05
      6,029.40
      3,630.90
      5,446.35
      7,261.80
      595,491.00
      893,236.50
      1,190,982.00
      329,160.00
      493,740.00
      658,320.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report